Jump to content
GET YOUR FLU VACCINE!

Search the Community

Showing results for tags 'challenging disease'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • The LuPUS Message Board
    • Announcements
    • What is the LuPUS Message Board?
    • A Welcome to New Members
    • User Problems
    • Links
  • Medical
    • Medical News 2003
    • Medical News 2004
    • Medical News 2005
    • Medical News 2006
    • Medical News 2007
    • Medical News 2008
    • Medical News 2009
    • Medical News 2010
    • Medical News 2011
    • Medical News 2012
    • Medical News 2013
    • Medical News 2014
    • Medical News 2015
    • Medical News 2016
    • Medical News 2017
    • Medical News 2018
    • Medical News 2019
    • Medical News 2020
    • Medical News 2021
    • Coronavirus: COVID-19
    • Medication & Therapy
    • Lupus and Pregnancy
    • Sjögren’s syndrome
    • Lymphoedema
    • Marginal Zone Lymphoma
  • Non-Medical
    • LuPUS Message Board
  • Public
    • Guest & Test Messages
    • Free Offers
    • Contributors

Blogs

  • Admin
  • Admin
  • Changes To My Diet For Health Reasons

Categories

There are no results to display.

There are no results to display.


Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


AIM


MSN


Website URL


ICQ


Yahoo


Jabber


Skype


Surname (Last or Family name)


First name


Date of Birth


Country


Location


Interests

Found 1 result

  1. Speakers: Lupus remains challenging disease July 6, 2017 Healio Rheumatology recently interviewed Richard Furie, MD, from Hofstra Northwell School of Medicine, Lars Rönnblom, MD, from Uppsala University in Sweden, and Peggy K. Crow, MD, from Hospital for Special Surgery, about the future of lupus during the Interferon Summit. “We need better drugs,” Furie said. “There is a major need for safer and more efficacious therapies. The typical patient who gets this disease is a young woman and it can be devastating.” SEE ALSO Furie discusses advances in SLE treatment Through the Cracks: Niche Patient Population Battles... Elusive Target: A Rundown of the Drug Pipeline for Systemic... Richard Furie To illustrate the need for better therapies, Furie discussed the progression of treatments for the disease. “We have come a long way with treatments,” he said. “If you go back before steroids were developed, the mortality was high. It was probably 50% at 7 years, but steroids were introduced and they have been a major advance. Then, after that, it was the immunosuppressives; but, until we get rid of all mortality and morbidity, we need new drugs.” To derive better therapies for a disease, there needs to be better disease classification. Rönnblom talked about the current classification of lupus patients and how to treat the underlying cause vs. a cluster of symptoms. “We classify patients with an auto[body] or antibody profile,” Rönnblom said. “In lupus, we classify them according to organ manifestation, but also when they have this interferon signature. My guess is that we will see more pathways coming up. Much of this data will be generated by the clinical trials, of course, who responds and who does not respond.” Lars Rönnblom Crow said better understanding about the molecular pathway and underlying mechanisms of the disease can lead to better therapy. “My own speculation is that we will probably end up with combination therapies and maybe combinations will allow us to use lower doses, each of one or two or three therapies to avoid toxicity. For example, we might want to target this type 1 interferon pathway that I believe is active in a sustained way throughout the disease, but may be more important in some stages than others,” she said. Peggy K. Crow “To have a more effective therapeutic activity, we might also want to target activated T cells or B cell differentiation. My guess is that we, as a community, will end up trying different combinations and some of the selection of those might be informed by the molecular pathways that an individual shows to be activated or abnormal.” – by Will A. Offit Disclosures: The researchers report no relevant financial disclosures. https://www.healio.com/rheumatology/lupus/news/online/{0b28f725-2f50-4168-b619-abd1de8a4266}/speakers-lupus-remains-challenging-disease?utm_source=selligent&utm_medium=email&utm_campaign=rheumatology news&m_bt=1879111151405
×
×
  • Create New...

Important Information